tiprankstipranks
Trending News
More News >
Travere, CSL Vifor report EC approval of Filspari for IgA nephropathy
PremiumThe FlyTravere, CSL Vifor report EC approval of Filspari for IgA nephropathy
12d ago
Travere, CSL Vifor announce EC approval of Filspari marketing authorization
Premium
The Fly
Travere, CSL Vifor announce EC approval of Filspari marketing authorization
12d ago
TVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
TVTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
12d ago
Travere Therapeutics price target raised to $31 from $29 at BofA
PremiumThe FlyTravere Therapeutics price target raised to $31 from $29 at BofA
1M ago
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed Amid Regulatory and Market Opportunities
Premium
Ratings
Promising Outlook for Travere Therapeutics: Buy Rating Affirmed Amid Regulatory and Market Opportunities
1M ago
Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS
Premium
Ratings
Buy Rating for Travere Therapeutics Driven by sNDA Submission and Market Potential in FSGS
2M ago
Travere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating
PremiumRatingsTravere Therapeutics: Strong Growth Potential and Strategic Advancements Justify Buy Rating
3M ago
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges
Premium
Company Announcements
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges
3M ago
Travere Therapeutics price target raised to $30 from $24 at TD Cowen
Premium
The Fly
Travere Therapeutics price target raised to $30 from $24 at TD Cowen
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100